Oncogenic MYC activation promotes cellular proliferation in Burkitt lymphoma (BL), but also induces cell cycle arrest and apoptosis mediated by TP53, a tumor suppressor gene that is mutated in 40% of BL cases. To identify therapeutic targets in BL, we investigated molecular dependencies in BL cell lines using RNAi-based, loss-of-function screening. By integrating genotypic and RNAi data, we identified a number of genotype-specific dependencies including the dependence of TCF3/ID3 mutant cell lines on TCF3 and of MYD88 mutant cell lines on TLR signaling. TP53 wild-type (TP53wt) BL were dependent on MDM4, a negative regulator of TP53. In BL cell lines, MDM4 knockdown induced cell cycle arrest and decreased tumor growth in a xenograft model in a p53-dependent manner, while small molecule inhibition of the MDM4-p53 interaction restored p53 activity resulting in cell cycle arrest. Consistent with the pathogenic effect of MDM4 upregulation in BL, we found that TP53wt BL samples were enriched for gain of chromosome 1q which includes the MDM4 locus. 1q gain was also enriched across non-BL cancer cell lines (n=789) without TP53 mutation (23% in TP53wt and 12% in TP53mut, p<0.001). In a set of 216 cell lines representing 19 cancer entities from the Achilles project, MDM4 was the strongest genetic dependency in TP53wt cell lines (p<0.001).
Introduction
Burkitt lymphoma (BL) is an aggressive B cell lymphoma that is characterized by translocation of the MYC gene to immunoglobulin loci (Molyneux et al., 2012) . While oncogenic MYC promotes cell growth and proliferation (Dalla-Favera et al., 1982; Taub et al., 1982) , it also evokes failsafe mechanisms such as p53 activation that have to be overcome for transformation (Evan et al., 1992; Meyer et al., 2006) . About 30% of BL acquire TP53 mutations and as a consequence cells do not respond to apoptotic stimuli (Bhatia et al., 1992; Gaidano et al., 1991; O'Connor et al., 1993) . As shown in mice, mutations in the conserved Myc box I prevent the induction of apoptosis via Bim as an alternative mechanism to TP53 mutation, providing further evidence that secondary lesions cooperate with oncogenic MYC induction (Hemann et al., 2005) .
Recent mutational cartography efforts in BL identified additional recurrent mutations in TCF3, ID3, GNA13, RET, PIK3R1, DDX3X, FBXO11 , and the SWI/SNF genes ARID1A and SMARCA4 (Kretzmer et al., 2015; Love et al., 2012; Richter et al., 2012; Schmitz et al., 2012) . BL also display copy number alterations (CNAs) in addition to the MYC translocation (Scholtysik et al., 2010) , targeting chromosomes 1q, 3p27, 13q31, 17p13 (including TP53) and 9p21.2 (including CDKN2A). A gain of 1q is found in 30% of BL and often affects large regions (Salaverria et al., 2008) , which has contributed to the limited understanding of oncogenic mechanisms involved. The clinical implications of these mutations and CNAs are currently unclear.
RNAi-based genomics screens allow querying of functional dependencies in an unbiased fashion and in high-throughput (Mohr et al., 2014) . Using panels of representative cell lines, context-specific vulnerabilities have been linked to genetic and pathological subgroups (Cheung et al., 2011) . The Achilles Project reported comprehensive screening data in 501 cell lines using RNAi (Cowley et al., 2014; Tsherniak et al., 2017) . While activating mutations caused direct oncogene addiction, as seen in cell lines with BRAF, KRAS or PI3K mutation, secondary gene dependencies were observed for loss-of-function mutations in tumor suppressor genes, such as ARID1A (Helming et al., 2014) . Integration of gene expression and drug sensitivity profiles may provide further insight into the molecular basis of diseases and might be used to tailor targeted therapies (Marcotte et al., 2016) .
For a comprehensive dissection of molecular dependencies in BL, we performed a loss-of-function RNAi screen across a panel of genetically characterized BL cell lines and intersected our findings on genotypespecific essential genes with the genetic profile of a well-annotated patient cohort.
Results

Landscape of essential genes in BL
To identify therapeutic targets in BL, we investigated molecular dependencies in BL cell lines using RNAibased loss-of-function screening. We used 27,495 shRNAs to silence 5,045 genes and assessed changes in shRNA abundance after culturing the cells for two weeks ( Figure 1A ). On average 24% of shRNAs were depleted at least two-fold and shRNAs targeting core essential complexes, including the ribosome and the proteasome, were specifically lost (68% and 47%, respectively) ( Figure 1B ). To evaluate the viability effect of individual gene knock-downs, we calculated weighted z-scores that combine the effect of shRNAs targeting the same gene and emphasize strong fold-changes (Dai et al., 2014; Kim and Tan, 2012 ) (see Methods). Common essential genes, as defined on the basis of previous RNAi screens (Hart et al., 2014) , showed significantly lower scores compared to non-essential genes (p<0.001, Figure 1C ).
Notably, while a subset of genes was essential in all cell lines, we also observed cell line specific viability effects ( Figure S1A , B).
To investigate essential genes in the context of BL, we probed our data against RNAi screening results using the same set of shRNAs in six carcinoma cell lines (C4-2, DU145, PC3, R22v1, MDA-MB-231, A2780) and three cell lines of myeloid and lymphoid origin (AML193, THP1, U937) ( Figure S1C , Table S1 ). We ranked shRNAs based on their differential effects between two cell line groups and calculated a gene classification score as a measurement of their strength to distinguish between the groups (Cheung et al., 2011) (Table S2) . We then selected genes that were predictors of an entity group and showed strong differential viability effects based on the weighted z-scores. Using this method, we identified 76 genes essential in BL, including genes associated with hematopoietic cell differentiation (FLI1, BCL11A) or B cell development and activation (PAX5, CDKN1B, JAK2, CARD11) ( Figure 1D , left). The transcription factor FLI1 is a key regulator of the hematopoietic system and B cell development (Zhang et al., 2008; Zochodne et al., 2000) . In our screen, knock-down of FLI1 was also toxic to blood-lineage derived non-BL cell lines, while PAX5, a marker of early B-cell development, was an essential gene exclusively in BL ( Figure 1D , middle/right).
Genotype-specific dependencies in BL
To identify exploitable vulnerabilities in the context of gene mutations, we performed RNA sequencing of the BL cell lines included in the RNAi screen. Genes that are recurrently mutated in BL, including TP53, ID3, TCF3, DDX3X, FOXO1 and GNA13 (Kretzmer et al., 2015; Love et al., 2012; Richter et al., 2012; Schmitz et al., 2012) , were represented by our cell line models (Table S3 ). We therefore investigated essential genes in the respective genotype groups. Mutations in the transcription factor TCF3 lead to oncogene activation and loss-of-function mutations of its inhibitor ID3 are often observed as a complementary mechanism of TCF3 activation (Schmitz et al., 2012) . Therefore, cell lines carrying either TCF3 or ID3 mutation were treated as one group. The four cell lines with TCF3/ID3 mutation were strongly dependent on TCF3 expression, indicating oncogene addiction (p<0.01) ( Figure 1E ). In line with the loss of function effect of mutations in ID3, ID3 silencing was not toxic ( Figure 1E, left) . The cell line BL-2 harbors the activating p.S219C mutation in MYD88, an adaptor protein involved in Toll-LikeReceptor signaling and NF-kB activation. Among the shRNAs that were toxic in the MYD88mut context, we identified an enrichment for shRNAs targeting MYD88 or its direct downstream mediator IRAK1 ( Figure 1F ). Encouraged by the ability to uncover oncogene addiction, we expanded our analysis of genotype-specific vulnerabilities to DDX3X, FOXO1, GNA13 and TP53 (Table S2 ; Figure S1D ). TP53 mutation was associated with the strongest differential viability effects (gene classification scores > 2) and we therefore focused on TP53-specific vulnerabilities (Figure 2A , left).
p53 pathway in BL
Based on shRNA depletion in four TP53 mutant (TP53mut) versus four TP53 wild-type (TP53wt) cell lines, we identified viability genes specific to both groups ( Figure 2A ). TP53mut cell lines were more sensitive to depletion of PSMB6 (Figure 2A , B) and additional proteasomal subunits ( Figure S2) . A gain-of-function phenotype of mutant p53 has been associated with increased proteasome activity (Walerych et al., 2016) and proteasome inhibition was shown to reduce mutant p53 expression (Halasi et al., 2014) . We also identified the heat shock protein HSPE1 as an essential gene in mutant cell lines (Figure 2A, B) .
Upon cellular stress, heat shock proteins regulate the stability of wild-type and mutant p53 and HSP90 inhibitors were shown to be effective in p53 mutant cell lines (Blagosklonny et al., 1996; Li et al., 2011; Muller et al., 2008) .
Genes essential in TP53wt cell lines included the cell cycle regulators CDKN3 (Figure 2A , B), a spindle checkpoint phosphatase activated by p21 (Baldi et al., 2011) . The strongest gene dependency of the TP53wt group was MDM4 (gene score=2.12; Figure 2A , left) that inactivates p53-mediated transcription by blocking of its transactivation domain (Shvarts et al., 1997) . Notably, as Epstein-Barr virus (EBV) associated proteins deregulate cell cycle checkpoints and quench the p53 pathway by deubiquitination of the p53 inhibitor MDM2 (Fish et al., 2017; Saha et al., 2009 ), we confirmed a balanced distribution of EBV infection status among TP53wt and TP53mut BL cell lines (Table S3) .
MDM4 is essential in TP53wt BL
shRNAs targeting MDM4 were more toxic in TP53wt than TP53mut cell lines ( Figure 2B ) and all shRNAs efficiently reduced MDM4 mRNA and protein levels ( Figure 2C ). Using two non-overlapping shRNAs, we validated the screen findings in a growth competition assay in all BL cell lines included in the RNAi screen and four additional TP53mut cell lines. shRNAs were co-expressed with red fluorescent protein (RFP) in ~50% of cells and the fraction of RFP+/shRNA+ cells was monitored over time. TP53wt cell lines (n=4) showed a significant reduction of cells with MDM4 knock-down, which was not observed for TP53mut cell lines (n=8), confirming the screen results ( Figure 2D ).
To further test whether the observed effects were dependent on p53, we generated a p53 knock-out cell line based on the TP53wt cell line Seraphine ( Figure S3 ). Seraphine-TP53ko showed a decreased basal apoptotic rate, while the cell cycle progression was unaffected ( Figure 3B , S3B). When we silenced MDM4 in Seraphine-TP53wt, we observed significantly stronger loss of RFP+ cells compared to Seraphine-TP53ko, confirming that the viability effects following MDM4 depletion were p53-dependent ( Figure 2E ).
MDM4 promotes cell cycle progression by p53 inactivation
To understand the downstream effects of MDM4 depletion in BL, we assessed protein levels of p53 and known p53 targets. MDM4 knock-down in TP53wt cells increased p53 protein level and induced the proapoptotic Bcl-2 family member PUMA and the cell cycle inhibitor p21 ( Figure 3A ). Since MDM4 downregulation did not cause apoptosis as determined by absence of PARP cleavage ( Figure 3A) , we analyzed the cell cycle profile in the presence or absence of functional p53 after MDM4 silencing. In the TP53wt context, shRNAs targeting MDM4 decreased cycling cells compared to a non-targeting shRNA (shNT, p<0.001), which was not observed in the TP53mut or the TP53ko cell line ( Figure 3B ).
We next determined global gene expression changes after MDM4 and MDM2 silencing in the TP53wt and TP53ko Seraphine cell lines ( Figure 3C , Table S4 ). Silencing of MDM4 or MDM2 induced strong changes only in the presence of p53 and affected similar pathways. Using gene set enrichment analysis for cancer hallmark genes (MSigDB), we identified p53 targets as the strongest upregulated pathway, while prominent survival and proliferation pathways, including MYC and E2F targets, were downregulated. This suggests that most effects were mediated by p53 activation, in accordance with a previous report on genes commonly regulated after MDM4 or MDM2 knock-down (Heminger et al., 2009) . We also compared genes differentially regulated by MDM2 or MDM4 silencing ( Figure S4 ). Downregulation of MYC and upregulation of CCND1 were exclusively seen after MDM4 knock-down, indicating potential differences in pathway contribution exerted by MDM4 over MDM2 ( Figure 3C , S4).
We next examined the basal protein and mRNA expression levels of p53, MDM4 and MDM2 in a panel of BL models ( Figure 3D ). p53 protein was detected at higher level in all TP53mut cell lines (p<0.01) as described previously (Bartek et al., 1991; Farrell et al., 1991) , while p53 mRNA levels were lower. While wild-type p53 is rapidly turned-over in a negative feed-back loop mediated by MDM2, mutant p53 protein accumulates as a result of disrupted proteasomal decay pathways (Vijayakumaran et al., 2015) .
MDM4 mRNA was significantly higher in TP53wt BL cell lines (p=0.05) and was correlated with protein expression (p<0.01) ( Figure 3D ). MDM2 levels were also elevated in TP53wt cell lines, but not significantly ( Figure 3D ).
MDM4 is a therapeutic target in TP53wt BL
To evaluate the potential of MDM4 as a therapeutic target in TP53wt BL in vivo, we determined the effect of MDM4 silencing on tumor growth in a mouse xenograft model. After transduction, cell lines representing TP53wt (Seraphine), TP53ko (Serphine-TP53ko) and TP53mut (Raji) were injected subcutaneously into the flanks of immunodeficient mice (Herhaus et al., 2016) . To quantify tumor formation and dynamic growth, we measured fludeoxyglucose (FDG) uptake in positron emission tomography (PET). In vivo tumor formation was significantly reduced after MDM4 knockdown in the presence of wild-type p53 (p<0.05) ( Figure 4A , B).
Restoration of p53 activity is an attractive therapeutic approach for treatment of cancer (Burgess et al., 2016) . The small molecule inhibitor Nutlin-3 targets the p53 inhibitor MDM2 and therefore restores signaling through the p53 pathway (Vassilev et al., 2004) . Nutlin-3 increased intracellular p53 level and induced apoptosis in Seraphine-TP53wt, but not in Seraphine-TP53-ko ( Figure S3A ). All TP53wt cell lines were sensitive to Nutlin-3 ( Figure 4C ). Despite the high sequence homology of MDM2 and MDM4, Nutlin-3 targets MDM2 with a much higher binding affinity (Patton et al., 2006) . Moreover, overexpression of MDM4 can lead to resistance against MDM2-targeting drugs (Hu et al., 2006; Patton et al., 2006) . We therefore tested the potential of combined inhibition of MDM4 and MDM2 in BL.
MDM4 knock-down increased cytotoxic effects of Nutlin-3 ( Figure 4D ). TP53wt cell lines were sensitive towards the dual-specificity inhibitor RO-5963, that targets MDM2 and MDM4 (Graves et al., 2012) ( Figure 4E ). This data provides a rational for targeting MDM4/2 in TP53wt BL.
Gain of MDM4 on chr1q provides an alternative to TP53 mutations in BL
To understand the role of the p53 pathway in BL, we analyzed the genetic profile of aggressive B-cell lymphomas stratified into BL, diffuse large B cell lymphoma (DLBCL) or cases with intermediate phenotype (Table S5) . TP53 mutations were found in 28/61 (45.9%) of BL samples and were significantly more frequent in BL than in DLBCL (p<0.001) ( Figure 5A ). MYC box I mutations were previously reported to be mutually exclusive with TP53 mutations and to serve as an alternative mechanism to escape apoptotic pathways in the presence of wild-type TP53 (Hemann et al., 2005) . MYC mutations were present in 37/56 BL samples (66.1%) and the MYC box I residues 56-58 were affected in 20 (35.7%) cases ( Figure 5B ). Notably, MYC box I mutations frequently co-occurred with TP53 mutations ( Figure 5B ).
We next explored the profile of copy number alterations in BL (n=56, Figure 5C , S5C). Deletion of 17p13, including the TP53 gene, was rare in BL, but co-occurred with TP53 mutation in 5/6 cases resulting in biallelic p53 inactivation. Loss of the p53 activator ARF (CDKN2A locus on 9p21.3), that has been described as an alternative mechanism of p53 inactivation (Lindstrom et al., 2001) , was rare in BL (n=1). The gain on chromosome 1q (chr1q+) affected 33.9% of BL and was the most common structural aberration besides MYC translocation. Unexpectedly, we observed an overrepresentation of chr1q+ in TP53wt BL (13/31, 41.9%) compared to TP53mut (6/25, 24%), suggesting a previously unappreciated connection of TP53 status and 1q gain in BL ( Figure 5B, C, S5C) . A detailed analysis of the architecture of 1q CNA based on single nucleotide polymorphism (SNP) array and comparative genomic hybridization (CGH) array data showed that chromosomal gains most frequently affected the proximal part of the chromosome and an additional peak at 1q32, including the location of MDM4 ( Figure 5D ). The association of chr1q gain with TP53 mutation status was specific to BL and was not observed in DLBCL (p=1) or intermediate (p=0 .654) lymphomas ( Figure S5A, B) .
Genes affected by the 1q gain included a number of known oncogenes, such as BCL9, MCL-1, CKS1B and MDM4, and gene clusters of the Fc receptor like (FCRL) and the Fc immunoglobulin receptor (FCGR) family that serve as potential targets for immunotherapy (Masuda et al., 2009 ). We therefore tested if BL cell lines from the RNAi screen were more dependent on genes on 1q ( Figure 5E , D). The RNAi library covered 235 genes located on 1q including all candidate genes except for the FCRL gene family. All four TP53wt BL cell lines were previously reported to carry a 1q gain (Toujani et al., 2009) . In Seraphine, the whole chromosomal arm was affected (+1q21.1qter), while partial gains were seen in BL-2 (+1q21.1q31.3), LY47 (+1q43q44), and Seraphine (+1q21.1qter). The TP53mut cell lines were diploid for 1q (Table S3) . Genes on 1q were not enriched for viability genes in the group of TP53wt or TP53mut BL cell lines, respectively ( Figure 5E ). Notably, MDM4 was the only gene showing TP53-specific viability effects after silencing ( Figure 5F ). Altogether, our data support a critical role for quenching of the p53 pathway in BL preferably by mutations of TP53 or amplification of MDM4, thereby identifying p53 signaling as the critical failsafe checkpoint in BL.
TP53 mutations and MDM4 gain inactivate the p53 pathway in primary BL
To study the functional consequences of p53 pathway aberrations, we generated a molecular signature that distinguished TP53wt and TP53mut B-cell non-Hodgkin-Lymphoma (B-NHL, n=430) using supervised hierarchical clustering ( Figure 6A ). The gene CDKN2A was significantly repressed in TP53wt BL (p<0.01), intermediate lymphoma (p<0.01) and DLBCL (p<0.01) samples ( Figure 6B ). Within the 50 most differentially expressed gene probes with lower expression in TP53mut patients, 28 were located on chr17p13, while 4 gene probes were located on chr1q. These findings reflect the gene dosage effect as a result of chr17p13 deletion in TP53mut and chr1q gain in TP53wt patients. Nine probes corresponding to six p53 target genes were overexpressed in TP53wt samples, demonstrating that a portion of aggressive B-NHL retain active p53 signaling. Notably, while MDM2, that is activated by p53 in a negative feedback loop, showed higher expression in TP53wt DLBCL (p<0.01) and BL (p=0.04) ( Figure   6C ), high MDM4 mRNA expression was specific to BL with TP53wt (p<0.01, Figure 6D ). Expression of MDM4 in TP53wt samples was independent of chr1q+, indicating that additional mechanisms regulate MDM4 expression ( Figure S6 ). Combined, these data provide evidence for upregulation of MDM4 in TP53wt BL as a disease driver.
MDM4 and TP53 mutation across cancer models
To investigate the role of chr1q gain in context of TP53 mutations across a range of cancers, we analyzed the associations between genetic aberrations in 789 cell lines with available SNP6.0 data and TP53 mutation data within the Cancer Cell Line Encyclopedia (Barretina et al., 2012) . Chr1q32 gain was identified in 122 cell lines (15.5%) and was associated with wild-type p53 (p<0.001, 23% in TP53wt and 12% in TP53mut) ( Figure 7A ).
We further combined genetic information with functional genomics data and investigated p53-dependent vulnerabilities in a set of 216 cell lines representing 19 cancer entities from the Achilles project (Cowley et al., 2014) . The p53 status was available for 182 cell lines and TP53 mutations were present in 70% of all cancer cell lines ( Figure 7B , Table S5 ). TP53 was identified as an essential gene in TP53mut cell lines, which is in line with its reported gain-of-function phenotype (Goldstein et al., 2011) ( Figure 7C) . MDM4 was the top ranked gene leading to impaired viability of TP53wt cell lines out of more than 10,000 genes investigated (p<0.001) ( Figure 7C , Table S7 ). All shRNAs targeting MDM4 were strongly depleted in TP53wt cell lines ( Figure 7D ). Eight cancer entities were represented with at least two TP53mut and two TP53wt cell lines which allowed us to explore MDM4 dependency in different cancer subtypes ( Figure 7E , Table S7 ). MDM4 was identified as an essential gene in TP53wt cell lines derived from the hematopoietic/lymphoid system (rank 1), large intestine (rank 3), breast carcinoma (rank 25) and ovarian carcinoma (rank 62) ( Figure 7F ). Cell lines originating from central nervous system (CNS), pancreas, bone and skin did not show p53-specific viability effects ( Figure 7F ).
MDM2 also showed significant shRNA depletion in TP53wt cell lines (p=0.004, rank 51, Figure 7C ).
Notably, p53-specific dependency on MDM2 were strongest in ovarian carcinoma (rank 20) and CNS (rank 8), suggesting disease-specific roles of MDM2 or MDM4 ( Figure 7F ).
Combined these data suggest a functional role for MDM4 as a critical cancer driver targeted by 1q gain across cancers.
Discussion
Genetic studies expanded our understanding of the pathogenesis of BL and functional genomics is a powerful tool to link genetic aberrations to novel molecular targets. This study dissected context-specific essential genes in BL. We observed a strong dependence of BL on PAX5, a key B-cell transcription factor previously linked to B-cell lymphomagenesis (Cozma et al., 2007) . A recent genetic perturbation screen using genome-wide CRISPR/Cas9 sgRNA libraries identified PAX5 as one of the top candidate genes essential in two BL cell lines . These findings are in line with a role of PAX5 as a "lineage-survival oncogene" (Ceribelli et al., 2016; Garraway and Sellers, 2006) . The increased capacity to drug transcription factors (Filippakopoulos et al., 2010) as well as the recent demonstration of the role of PAX5 as a metabolic gatekeeper (Chan et al., 2017) suggests that PAX5 targeting may provide a novel therapeutic strategy.
We systematically queried genotype-specific vulnerabilities of BL and identified oncogene dependency on TCF3 of TCF3/ID3 mutant BL, and dependency on MYD88 and IRAK1 in a cell line with MYD88 mutation in line with previous results in DLBCL cell lines (Ngo et al., 2011) . The strongest dependency was observed for TP53wt cell lines on MDM4. While BL displays with a high rate of TP53 mutations (higher than e.g. DLBCL), alternative mechanisms must be exploited in the cells retaining TP53wt. The dependency of TP53wt BL cell lines on MDM4 provides additional evidence for the importance of suppressing p53-mediated stress signals. Reactivation of p53 by inhibition of MDM4 has been shown to be a promising therapeutic target in melanomas Gembarska et al., 2012) and breast carcinomas . We validated MDM4 as a therapeutic target in TP53wt BL in a mouse xenograft model and MDM4 silencing enhanced the cytotoxic effect of MDM2 inhibition.
Based on a pan-cancer analysis, we show that MDM4 targeting could be exploited therapeutically across cancers with TP53wt and we confirmed the association of 1q gain and cancers retaining TP53wt. Our findings provide a rational for further clinical development of dual MDM2/MDM4 inhibitors for BL and other TP53wt cancers.
Chromosome 1q gain is the most frequent copy number alteration across cancer (Beroukhim et al., 2010) . Functional evidence for disease drivers targeted by 1q gain has been scarce. In BL, studies of CNA identified gains for 1q25.1 and 1q31.3 and suggested PTPRC, a regulator of B-cell receptor and cytokine signaling, and two annotated miRNA genes (hsa-mir-181b-1 and -213) as strong candidates (Scholtysik et al., 2010) . A study of primary tumors and cell lines identified BCA2 and PIAS3 on 1q21.-1q21.3, MDM4 on 1q32.1 and AKT3 on 1q44 as possible drivers (Toujani et al., 2009) . Our data provides functional evidence that 1q gain targets MDM4 as an essential gene in TP53wt BL. Based on the incidence of TP53 mutation and 1q gain in the disease, our findings suggest a widespread mechanism to quench p53 activity in BL, likely as a way to quench p53 mediated failsafe mechanisms elicited by MYC overexpression.
Combined, these data provide functional evidence that 1q gain targets MDM4 as a disease driver across cancer. TP53 mutations and 1q gains were reported as the frequent lesions associated with postmyeloproliferative-neoplasm AML and mutual exclusivity has been reported in this setting (Harutyunyan et al., 2011) . Copy number changes of MDM4 and MDM2 have been reported to occur exclusively in bladder TP53wt tumors (Veerakumarasivam et al., 2008) . A study by Monti et al identified a comprehensive set of CNAs that decreased p53 activity and perturbed cell cycle regulation in DLBCL (Monti et al., 2012) .
Our data suggest that among lymphomas, BL exhibits disease specific mechanisms of p53 pathway quenching through TP53 mutation and MDM4 overexpression. A major open question pertains to the selective advantage of MDM4 or MDM2 overexpression in TP53wt cancers. Although MDM4 and MDM2 are highly homologous, MDM4 lacks E3 ligase activity and depends on MDM2 to promote p53 degradation (Linares et al., 2003) . In our study, we identified downregulation of MYC and upregulation of CCND1 exclusively after MDM4 knock-down, indicating differences in pathway contribution exerted by MDM4 over MDM2. p53-independent oncogenic activities have been previously associated with MDM4. MDM4 was shown to promote pRb degradation by MDM2, with consequent E2F1 activation of the cell cycle (Zhang et al., 2015) . MDM4 contributes to p53 inhibition by suppressing its transcriptional activity, and also by partnering with MDM2 to regulate p53 degradation (Francoz et al., 2006) . (C) Global gene expression changes after MDM4 and MDM2 knock-down in isogenic Seraphine cell lines.
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Expression levels were normalized to shNT and gene set enrichment analysis was performed in the TP53wt cell line using the java GSEA software (http://software.broadinstitute.org/gsea/downloads.jsp).
Enrichment curves for the most enriched pathways are shown below the volcano plots. Genes from suppressed pathways are highlighted in blue and genes from enriched pathways in green. Genes highlighted in red were changed after MDM4, but not after MDM2 knock-down (cut-off -log10(p-value) > 2, log2(fold-change) < -0.5 or > 0.5). (C) Cell line sensitivity to Nutlin-3 stratified by TP53 mutation. Ten TP53mut, seven TP53wt and one TP53ko BL cell line were exposed to Nutlin-3 for 48h and viability was assayed by ATP content and normalized to DMSO treated samples. (E) TP53 mutation status for 216 cell lines from the Achilles Project by cancer entity.
(F) Entity-specific analysis of TP53-dependent viability genes. Gene ranking was performed for all entities that had at least two cell lines per class as described for (C). conditions. Cell line authentification was performed using Multiplex Cell Authentification by Multiplexion (Heidelberg, Germany) as described previously (Castro et al., 2013) . The SNP profiles matched with known ones in the databse or were unique. Cell lines were tested for contamination using the Multiplexion cell Contamination test (Heidelberg, Germany) as described previously (Schmitt and Pawlita, 2009 ).
Supplementary tables Supplementary
RNAi screen. The RNAi screen was performed as described previously using the Cellecta human Module I pooled lentiviral shRNA library (Slabicki et al., 2016) . Cells were harvested on day 2 (one replicate) or day 14 (2 replicates) post-transduction. p-values for shRNA depletion were calculated with the edgeR package (Dai et al., 2014) and shRNA p-values were collapsed into gene scores using weighted Ztransformation (Kim and Tan, 2012) . For comparison of differential shRNA effects between two groups, log2-transformed shRNA fold-changes were scaled with peak median absolute deviation (PMAD) normalization using the GenePattern module NormLines (Cheung et al., 2011; Reich et al., 2006) . Using the GENE-E software (https://software.broadinstitute.org/GENE-E/index.html), p-values for differential shRNA effects were calculated and collapsed into gene scores using Kolmogorov-Smirnov statistics (Cheung et al., 2011) . RNAi results in non-BL cell lines were provided by Cellecta Inc. as raw read counts.
Genome-wide RNAi results in 216 cell lines were provided as log2-transformed shRNA fold-changes (Cowley et al., 2014) . Genetic information on cell lines was extracted from CCLE (https://portals.broadinstitute.org/ccle/home) and COSMIC (GDSC, http://www.cancerrxgene.org/). shRNAs were mapped against the human transcriptome (Ensembl v75) using Tophat2 algorithm and genes that scored with shRNAs targeting non-overlapping sequences were considered as candidate genes. For single gene knock-downs, shRNAs were expressed in the pRSI12-U6-(sh)-UbiC-TagRFP-2A-Puro vector backbone. Packaging of constructs into lentiviral particles was performed as described previously (Slabicki et al., 2016) . shMDM4_1: 5'-GTTCACTGTTAAAGAGGTCAT-3'; shMDM4_2: 5'-CACCTAGAAGTAATGGCTCAA-3'; shMDM2_1: 5'-CTTTGGTAGTGGAATAGTGAA-3'.
RNA sequencing. mRNA sequencing libraries were prepared from 1 µg of total RNA using Illumina TruSeq R RNA sample preparation v2 (Illumina, San Diego, CA, USA) and multiplexed samples were Imaging System (Cell Signaling) was used for detection.
Generation of isogenic cell lines. sgRNAs targeting p53 were cloned into lentiCRISPRv2, which was a gift from Feng Zhang (Addgene, Cambridge, MA, USA, plasmid #52961) (Sanjana et al., 2014) . Seraphine cells modified with lentiCRISPRv2-sgTP53 were selected using puromycin and Nutlin-3. sgTP53: 5'-CCCCTTGCCGTCCCAAGCAA-3'. Cell cycle profiling/apoptosis assay. Analysis of cell cycle phases was performed using the BrdU Flow Kit (BD Pharmingen), including Annexin-V to stain for apoptotic cells according to the manufacturer´s protocols.
Gene expression analysis. Global gene expression changes after MDM4 and MDM2 knock-down were analyzed by hybridization of total RNA on a Illumina BeadChip HumanHT-12-v4 containing >47,000
probes for 31,000 annotated human genes. To identify biological processes correlated with differentially expressed genes, the Gene Set Enrichment Analysis (GSEA) software was used with the C2 and H gene sets from the MSigDB database (http://software.broadinstitute.org/gsea/msigdb) (Mootha et al., 2003; Subramanian et al., 2005) .
Xenograft model. Animal studies were performed in agreement with the Guide for Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication n. 85-23, revised 1996) , in compliance with the German law on the protection of animals, and with the approval of the regional authorities responsible (Regierung von Oberbayern). The in-vivo experiments were performed as published previously (Herhaus et al., 2016) . Briefly, Seraphine-TP53wt, Seraphine-p53ko and Raji cell lines were infected in vitro with shNT or shMDM4 aiming at > 80% transduction efficiency. 1x10^7 cells were subcutaneously injected into flanks of immunodeficient mice. Tumor growth was monitored by FDG-PET after 11 or 16 days depending on the graft efficiency and mice were sacrificed.
Luminescent growth assay. Cell viability and growth were measured by detection of ATP level using the CellTiter-Glo luminescent assay (Promega, Madison, WI) as described (Dietrich et al., 2018) .
Primary sample analysis. Copy number alterations were analyzed by CGH using a BAC/PAC array that consisted of 2799 DNA fragments as described elsewhere (Fiegler et al., 2003; Schwaenen et al., 2004) .
Interphase FISH analysis was performed on paraffin-embedded or frozen tissue sections to determine MYC, BCL2 and BCL6 translocations to IG regions. TP53 mutations were determined by DHPLC and sequencing of exons 4-10 of the coding region (Zenz et al., 2010) . The expression data of primary samples was downloaded from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo, accession numbers GSE43677, GSE21597). Patients were classified into BL, DLBCL and an intermediate group based on a previously described molecular signature (Hummel et al., 2006) . For all samples, tumor cell content exceeded 70%.
